Sinotherapeutics Inc.

SHSE:688247 Stock Report

Market Cap: CN¥5.0b

Sinotherapeutics Past Earnings Performance

Past criteria checks 3/6

Sinotherapeutics has been growing earnings at an average annual rate of 1.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 12.6% per year. Sinotherapeutics's return on equity is 8.9%, and it has net margins of 24.4%.

Key information

1.9%

Earnings growth rate

-1.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate12.6%
Return on equity8.9%
Net Margin24.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Nov 02
Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Recent updates

Optimistic Investors Push Sinotherapeutics Inc. (SHSE:688247) Shares Up 27% But Growth Is Lacking

Nov 08
Optimistic Investors Push Sinotherapeutics Inc. (SHSE:688247) Shares Up 27% But Growth Is Lacking

Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Nov 02
Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Revenue & Expenses Breakdown

How Sinotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688247 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244491105287
30 Jun 24407924980
31 Mar 24369764879
31 Dec 23300614574
30 Sep 23274704468
30 Jun 23230764168
31 Mar 23227804268
31 Dec 22248934676
30 Sep 222711414382
30 Jun 222871384386
31 Mar 223011374396
31 Dec 2131513546104
31 Dec 203191235776
31 Dec 1913955451
31 Dec 1861-373350

Quality Earnings: 688247 has a high level of non-cash earnings.

Growing Profit Margin: 688247's current net profit margins (24.4%) are lower than last year (25.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688247 has become profitable over the past 5 years, growing earnings by 1.9% per year.

Accelerating Growth: 688247's earnings growth over the past year (56.7%) exceeds its 5-year average (1.9% per year).

Earnings vs Industry: 688247 earnings growth over the past year (56.7%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 688247's Return on Equity (8.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinotherapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution